- Home
- SLI vs RDHL Comparison
SLI vs RDHL Comparison
Compare SLI & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | RDHL |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.8M | 3.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLI | RDHL |
|---|---|---|
| Price | $4.60 | $1.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 68.5K |
| Earning Date | 11-10-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $1.08 | $1.01 |
| 52 Week High | $6.40 | $7.44 |
Technical Indicators
Market Signals| Indicator | SLI | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 49.36 |
| Support Level | $4.60 | $1.18 |
| Resistance Level | $4.93 | $1.26 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 74.17 | 78.00 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.